For more details on this clinical trial, including contact information, please see this trial’s listing on clinicaltrials.gov:
The goal of this clinical research study is to learn if ixazomib can prevent AML or MDS from coming back in patients who are in remission. The safety of this drug will also be studied.
Sun, 03/01/2015 to Mon, 03/01/2021
Bone Marrow Disease(s):
myelodysplastic syndromes (MDS)
Drug: Ixazomib 4 mg by mouth on Days 1, 8 and 15 of each 28-day cycle. Other Name: MLN9708